Paysign (PAYS) investor relations material

Strategic position and business model

• Holds approximately 45.5% share of the U.S. plasma payments market, serving 554 facilities and 8.4M cardholders.

• Operates a dual-engine platform: plasma donor compensation and pharmaceutical patient affordability solutions.

• Proprietary Dynamic Business Rules technology delivers 97% first-fill detection accuracy, protecting manufacturer funds and patient access.

• Integrated payments and workflow engine spans healthcare and financial rails, with high regulatory compliance (HIPAA, PCI DSS, pending FDA 510(k)).

• Capital-light model with zero bank debt and high gross margins (59.4% in FY2025).

Financial performance and growth

• FY2025 revenue reached $82.0M (+40.5% YoY), with adjusted EBITDA of $19.9M (+107.3% YoY) and a 24.3% EBITDA margin.

• Patient affordability revenue grew 167.8% YoY to $33.9M in FY2025, now 41.3% of total revenue.

• Plasma revenue was $45.6M in FY2025 (+4.0% YoY), with steady, recurring growth.

• Five consecutive years of double-digit top-line growth; cumulative 2021–2025 revenue growth of 178%.

• FY2026 guidance: $106.5M–$110.5M revenue (+30–35% YoY), $30.0M–$33.0M adjusted EBITDA, with a balanced plasma/PA split.

Operational platform and technology

• Fixed infrastructure enables scalable growth across both business lines, with revenue outpacing SG&A expense growth.

• Apherion™ platform provides modular SaaS for plasma and blood collection centers, integrating donor engagement, CRM, BECS, compensation, and analytics.

• Real-time, transaction-level fraud detection and compliance features embedded in both plasma and pharma workflows.

• Seamless program transitions and transparent pricing drive manufacturer retention in patient affordability programs.

• Recurring revenue models: per-donation transactions and software subscriptions for plasma; setup, management, and per-claim fees for pharma.